Claims:

Claim 1. An antigen-binding molecule, optionally isolated, which binds to gp130, wherein the antigen-binding molecule inhibits IL-6-mediated signalling, IL-11-mediated signalling, OSM-mediated signalling, CNTF-mediated signalling, CT-1-mediated signalling, and LIF-mediated signalling.

Claim 2. The antigen-binding molecule according to claim 1, wherein the antigen-binding molecule contacts the region of gp130 shown in SEQ ID NO:89.

Claim 3. The antigen-binding molecule according to claim 1 or claim 2, wherein:
(i) the antigen-binding molecule comprises:
(a)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:2
HC-CDR2 having the amino acid sequence of SEQ ID NO:3
HC-CDR3 having the amino acid sequence of SEQ ID NO:4; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:10
LC-CDR2 having the amino acid sequence of SEQ ID NO:11
LC-CDR3 having the amino acid sequence of SEQ ID NO:12; or
(b)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:2
HC-CDR2 having the amino acid sequence of SEQ ID NO:3
HC-CDR3 having the amino acid sequence of SEQ ID NO:185; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:10
LC-CDR2 having the amino acid sequence of SEQ ID NO:192
LC-CDR3 having the amino acid sequence of SEQ ID NO:12; or
(c)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:2
HC-CDR2 having the amino acid sequence of SEQ ID NO:3
HC-CDR3 having the amino acid sequence of SEQ ID NO:185; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:10
LC-CDR2 having the amino acid sequence of SEQ ID NO:11
LC-CDR3 having the amino acid sequence of SEQ ID NO:12; or
(d)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:2

HC-CDR2 having the amino acid sequence of SEQ ID NO:3

HC-CDR3 having the amino acid sequence of SEQ ID NO:4; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:10

LC-CDR2 having the amino acid sequence of SEQ ID NO:192

LC-CDR3 having the amino acid sequence of SEQ ID NO:12;

(ii) the antigen-binding molecule comprises:

(i) a VH region having an amino acid sequence having at least 70% amino acid sequence identity to a VH sequence as indicated in Column A of row 68, 71, 69, 72, 70, 73, 12, 13, 38-67, 3-11 or 1 of Table C, and

(ii) a VL region having an amino acid sequence having at least 70% amino acid sequence identity to a VL sequence as indicated in Column B of row 68, 71, 69, 72, 70, 73, 12, 13, 38-67, 3-11 or 1 of Table C,

wherein the VH and VL sequences are selected from the same row of Table C;

(iii) the antigen-binding molecule comprises:

(a)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:218; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(b)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:204; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(c)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:20; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(d)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:195; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(e)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:214; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(f)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:215; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(iv) the antigen-binding molecule comprises:

(i) a VH region having an amino acid sequence having at least 70% amino acid sequence identity to a VH sequence as indicated in Column A of row 89, 90, 80-88, 74-79 or 2 of Table C, and

(ii) a VL region having an amino acid sequence having at least 70% amino acid sequence identity to a VL sequence as indicated in Column B of row 89, 90, 80-88, 74-79 or 2 of Table C,

wherein the VH and VL sequences are selected from the same row of Table C.

Claim 4. The antigen-binding molecule according to any one of claims 1 to 3, wherein the antigen-binding molecule is a multispecific antigen-binding molecule, and wherein the antigen-binding molecule further comprises an antigen-binding domain which binds to an antigen other than gp130.

Claim 5. A chimeric antigen receptor (CAR) comprising an antigen-binding molecule according to any one of claims 1 to 4.

Claim 6. A nucleic acid, or a plurality of nucleic acids, optionally isolated, encoding an antigen-binding molecule according to any one of claims 1 to 4, or a CAR according to claim 5.

Claim 7. An expression vector, or a plurality of expression vectors, comprising a nucleic acid or a plurality of nucleic acids according to claim 6.

Claim 8. A cell comprising an antigen-binding molecule according to any one of claims 1 to 4, a CAR according to claim 5, a nucleic acid or a plurality of nucleic acids according to claim 6, or an expression vector or a plurality of expression vectors according to claim 7.

Claim 9. A method comprising culturing a cell according to claim 8 under conditions suitable for expression of an antigen-binding molecule or CAR by the cell.

Claim 10. A composition comprising an antigen-binding molecule according to any one of claims 1 to 4, a CAR according to claim 5, a nucleic acid or a plurality of nucleic acids according to claim 6, an expression vector or a plurality of expression vectors according to claim 7, or a cell according to claim 8, and a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

Claim 11. An antigen-binding molecule according to any one of claims 1 to 4, a CAR according to claim 5, a nucleic acid or a plurality of nucleic acids according to claim 6, an expression vector or a plurality of expression vectors according to claim 7, a cell according to claim 8, or a composition according to claim 10, for use in a method of medical treatment or prophylaxis.

Claim 12. Use of an antigen-binding molecule according to any one of claims 1 to 4, a CAR according to claim 5, a nucleic acid or a plurality of nucleic acids according to claim 6, an expression vector or a plurality of expression vectors according to claim 7, a cell according to claim 8, or a composition according to claim 10, in the manufacture of a medicament for treatment or prevention of: pathological inflammation, fibrosis, a disease/condition characterised by inflammation, a disease/condition characterised by fibrosis, a disease/condition characterised by inflammation and fibrosis, a disease/condition in which signalling through a gp130-containing complex is pathologically-implicated, a disease/condition in which a cytokine that signals through a gp130-containing complex is pathologically-implicated, an autoimmune disease, metabolic syndrome, a neurodegenerative disease, a chronic inflammatory disease, arthritis, rheumatoid arthritis, juvenile arthritis, systemic juvenile idiopathic arthritis, lupus, systemic lupus erythematosus, pancreatitis, thyroiditis, periodontitis, rhinitis, allergic rhinitis, dermatitis, atopic dermatitis, psoriasis, Hermansky-Pudlak syndrome, Graves' disease, obesity, insulin resistance, diabetes, type 1 diabetes, type 2 diabetes, pregnancy-associated hyperglycemia, multiple sclerosis, giant cell arteritis, Takayasu arteritis, cardiovascular disease, atherosclerosis, atrial fibrillation, ventricular fibrillation, cardiac hypertrophy, hypertrophic cardiomyopathy, dilated cardiomyopathy, myocarditis, cardiogenic shock, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, ischemic heart disease, myocardial infarction, Marfan syndrome, systemic

sclerosis, keloid, scleroderma, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, hippocampal atrophy, pulmonary disease, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, hepatitis, liver fibrosis, cirrhosis, hepatotoxicity, acetaminophen-induced hepatotoxicity, alcoholic liver disease, pancreatitis, steatosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestasis, primary biliary cholangitis, primary sclerosing cholangitis, inflammatory bowel disease, Crohn's disease, colitis, ulcerative colitis, endometriosis, stroke, ischemic stroke, nephropathy, kidney injury, acute kidney injury, nephrotoxicity, glomerulonephritis, chronic kidney disease, kidney fibrosis, Alport syndrome, adult-onset Still's disease, Castleman's disease, cytokine release syndrome, sepsis, septic shock, a retinal disorder, retinal fibrosis, age-related macular degeneration, wet age-related macular degeneration, retinitis pigmentosa, dry eye syndrome, COVID-19, Peutz-Jeghers syndrome, a skeletal muscle disorder, muscular dystrophy, amyotrophy, cachexia, an endocrine disorder, polycystic ovary syndrome, a cancer, a hematologic malignancy, leukemia, plasmacytoma, Hodgkin's lymphoma, lung cancer, colorectal cancer, intestinal cancer, urinary cancer, bladder cancer, vulvar cancer, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, bone cancer, glioblastoma, breast cancer, stomach cancer, renal cancer, metastatic renal cell cancer, skin cancer, melanoma, liver cancer, hepatocellular carcinoma, frailty, age-related increase in fat mass, sarcopenia, age-related hyperlipidaemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related liver steatosis, age-related non-alcoholic fatty liver disease, age-related non-alcoholic fatty liver, age-related non-alcoholic steatohepatitis, age-related cardiovascular disease, age-related hypertension, age-related renal disease, age-related skin disease, an infectious disease, a viral disease, viral hepatitis, hepatitis B, HIV infection, influenza infection, malaria, tuberculosis, an allergic disease, transplant rejection and graft-versus-host disease.

Claim 13. An *in vitro* complex, optionally isolated, comprising an antigen-binding molecule according to any one of claims 1 to 4 bound to gp130.

Claim 14. A method of selecting or stratifying a subject for treatment with a gp130-targeted agent, the method comprising contacting, *in vitro*, a sample from the subject with an antigen-binding molecule according to any one of claims 1 to 4, and detecting the formation of a complex of the antigen-binding molecule with gp130.

Claim 15. Use of an antigen-binding molecule which binds to gp130 and inhibits IL-6-mediated signalling, IL-11-mediated signalling, OSM-mediated signalling, CNTF-mediated signalling, CT-1-mediated signalling, and LIF-mediated signalling in the manufacture of a medicament for treatment or prevention of: pathological inflammation, fibrosis, a disease/condition characterised by inflammation, a disease/condition characterised by fibrosis, a disease/condition characterised by inflammation and fibrosis, a disease/condition in which signalling through a gp130-containing complex is pathologically-implicated, a disease/condition in which a cytokine that signals through a gp130-containing complex is pathologically-implicated, an autoimmune disease, metabolic syndrome, a neurodegenerative disease, a chronic inflammatory disease, arthritis, rheumatoid arthritis, juvenile arthritis, systemic juvenile idiopathic

arthritis, lupus, systemic lupus erythematosus, pancreatitis, thyroiditis, periodontitis, rhinitis, allergic rhinitis, dermatitis, atopic dermatitis, psoriasis, Hermansky-Pudlak syndrome, Graves' disease, obesity, insulin resistance, diabetes, type 1 diabetes, type 2 diabetes, pregnancy-associated hyperglycemia, multiple sclerosis, giant cell arteritis, Takayasu arteritis, cardiovascular disease, atherosclerosis, atrial fibrillation, ventricular fibrillation, cardiac hypertrophy, hypertrophic cardiomyopathy, dilated cardiomyopathy, myocarditis, cardiogenic shock, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, ischemic heart disease, myocardial infarction, Marfan syndrome, systemic sclerosis, keloid, scleroderma, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, hippocampal atrophy, pulmonary disease, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, hepatitis, liver fibrosis, cirrhosis, hepatotoxicity, acetaminophen-induced hepatotoxicity, alcoholic liver disease, pancreatitis, steatosis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, cholestasis, primary biliary cholangitis, primary sclerosing cholangitis, inflammatory bowel disease, Crohn's disease, colitis, ulcerative colitis, endometriosis, stroke, ischemic stroke, nephropathy, kidney injury, acute kidney injury, nephrotoxicity, glomerulonephritis, chronic kidney disease, kidney fibrosis, Alport syndrome, adult-onset Still's disease, Castleman's disease, cytokine release syndrome, sepsis, septic shock, a retinal disorder, retinal fibrosis, age-related macular degeneration, wet age-related macular degeneration, retinitis pigmentosa, dry eye syndrome, COVID-19, Peutz-Jeghers syndrome, a skeletal muscle disorder, muscular dystrophy, amyotrophy, cachexia, an endocrine disorder, polycystic ovary syndrome, a cancer, a hematologic malignancy, leukemia, plasmacytoma, Hodgkin's lymphoma, lung cancer, colorectal cancer, intestinal cancer, urinary cancer, bladder cancer, vulvar cancer, endometrial cancer, ovarian cancer, prostate cancer, pancreatic cancer, bone cancer, glioblastoma, breast cancer, stomach cancer, renal cancer, metastatic renal cell cancer, skin cancer, melanoma, liver cancer, hepatocellular carcinoma, frailty, age-related increase in fat mass, sarcopenia, age-related hyperlipidaemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related liver steatosis, age-related non-alcoholic fatty liver disease, age-related non-alcoholic fatty liver, age-related non-alcoholic steatohepatitis, age-related cardiovascular disease, age-related hypertension, age-related renal disease, age-related skin disease, an infectious disease, a viral disease, viral hepatitis, hepatitis B, HIV infection, influenza infection, malaria, tuberculosis, an allergic disease, transplant rejection and graft-versus-host disease, wherein the antigen-binding molecule contacts the region of gp130 shown in SEQ ID NO:89.

Claim 16. Use of an antigen-binding molecule that binds to gp130 and that contacts the region of gp130 shown in SEQ ID NO:89 to inhibit IL-6-mediated signalling, IL-11-mediated signalling, OSM-mediated signalling, CNTF-mediated signalling, CT-1-mediated signalling, and/or LIF-mediated signalling.

Claim 17. A method for inhibiting IL-6-mediated signalling, IL-11-mediated signalling, OSM-mediated signalling, CNTF-mediated signalling, CT-1-mediated signalling, and/or LIF-mediated signalling, comprising contacting cells capable of IL-6-mediated signalling, IL-11-mediated signalling, OSM-mediated signalling, CNTF-mediated signalling, CT-1-mediated signalling, and/or LIF-mediated signalling with an

antigen-binding molecule that binds to gp130 and that contacts the region of gp130 shown in SEQ ID NO:89.

Claim 18. The use according to claim 15 or claim 16, or the method according to claim 17, wherein:
(i) the antigen-binding molecule comprises:
(a)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:2
HC-CDR2 having the amino acid sequence of SEQ ID NO:3
HC-CDR3 having the amino acid sequence of SEQ ID NO:4; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:10
LC-CDR2 having the amino acid sequence of SEQ ID NO:11
LC-CDR3 having the amino acid sequence of SEQ ID NO:12; or
(b)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:2
HC-CDR2 having the amino acid sequence of SEQ ID NO:3
HC-CDR3 having the amino acid sequence of SEQ ID NO:185; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:10
LC-CDR2 having the amino acid sequence of SEQ ID NO:192
LC-CDR3 having the amino acid sequence of SEQ ID NO:12; or
(c)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:2
HC-CDR2 having the amino acid sequence of SEQ ID NO:3
HC-CDR3 having the amino acid sequence of SEQ ID NO:185; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:10
LC-CDR2 having the amino acid sequence of SEQ ID NO:11
LC-CDR3 having the amino acid sequence of SEQ ID NO:12; or
(d)
(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:2
HC-CDR2 having the amino acid sequence of SEQ ID NO:3
HC-CDR3 having the amino acid sequence of SEQ ID NO:4; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:10
LC-CDR2 having the amino acid sequence of SEQ ID NO:192
LC-CDR3 having the amino acid sequence of SEQ ID NO:12;

(ii) the antigen-binding molecule comprises:

(i) a VH region having an amino acid sequence having at least 70% amino acid sequence identity to a VH sequence as indicated in Column A of row 68, 71, 69, 72, 70, 73, 12, 13, 38-67, 3-11 or 1 of Table C, and

(ii) a VL region having an amino acid sequence having at least 70% amino acid sequence identity to a VL sequence as indicated in Column B of row 68, 71, 69, 72, 70, 73, 12, 13, 38-67, 3-11 or 1 of Table C,

wherein the VH and VL sequences are selected from the same row of Table C;

(iii) the antigen-binding molecule comprises:

(a)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:218; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(b)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:204; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(c)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:20; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(d)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:195; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(e)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:214; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(f)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:18

HC-CDR2 having the amino acid sequence of SEQ ID NO:19

HC-CDR3 having the amino acid sequence of SEQ ID NO:215; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:26

LC-CDR2 having the amino acid sequence of SEQ ID NO:27

LC-CDR3 having the amino acid sequence of SEQ ID NO:28; or

(iv) the antigen-binding molecule comprises:

(i) a VH region having an amino acid sequence having at least 70% amino acid sequence identity to a VH sequence as indicated in Column A of row 89, 90, 80-88, 74-79 or 2 of Table C, and

(ii) a VL region having an amino acid sequence having at least 70% amino acid sequence identity to a VL sequence as indicated in Column B of row 89, 90, 80-88, 74-79 or 2 of Table C,

wherein the VH and VL sequences are selected from the same row of Table C;

(v) the antigen-binding molecule further comprises an antigen-binding domain which binds to an antigen other than gp130.